LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Inicio・Lista de Acciones・Kura Oncology Inc

Kura Oncology Inc

Cerrado

SectorSanidad

10.4 -6.64

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

10.38

Máximo

11.32

Métricas clave
By Trading Economics
Ingresos	7.7M -73M
Ventas	929K 18M
Margen de beneficios	-401.495
Empleados	260
EBITDA	7.4M -78M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+149.87% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-31M 813M
Apertura anterior	17.04
Cierre anterior	10.4

Noticias sobre sentimiento de mercado

By Acuity

50%

159 / 345 Clasificación en Healthcare

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 may 2026, 08:24 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 may 2026, 21:22 UTC

Ganancias

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 may 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Basic Materials Roundup: Market Talk

25 may 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Basic Materials Roundup: Market Talk

25 may 2026, 16:01 UTC

Charlas de Mercado

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 may 2026, 14:43 UTC

Charlas de Mercado

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 may 2026, 14:15 UTC

Charlas de Mercado

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 may 2026, 13:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

25 may 2026, 12:58 UTC

Charlas de Mercado

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 may 2026, 12:56 UTC

Charlas de Mercado

Ganancias

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 may 2026, 12:48 UTC

Charlas de Mercado

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 may 2026, 12:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 may 2026, 12:34 UTC

Charlas de Mercado

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 may 2026, 12:10 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Delivery Hero's Assets Look Strategic -- Market Talk

25 may 2026, 11:00 UTC

Charlas de Mercado

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 may 2026, 10:19 UTC

Charlas de Mercado

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 may 2026, 10:05 UTC

Ganancias

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 may 2026, 10:04 UTC

Ganancias

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 may 2026, 10:03 UTC

Ganancias

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 may 2026, 10:02 UTC

Ganancias

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 may 2026, 10:01 UTC

Ganancias

Tenaga Nasional 1Q Net Up 3.7% on Year

25 may 2026, 10:00 UTC

Ganancias

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q EPS MYR0.1883

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q Rev MYR17.1B

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q Net MYR1.1B

25 may 2026, 09:38 UTC

Charlas de Mercado

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 may 2026, 09:33 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

25 may 2026, 09:33 UTC

Charlas de Mercado

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 may 2026, 08:55 UTC

Charlas de Mercado

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

149.87% repunte

Estimación a 12 Meses

Media 28.11 USD 149.87%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

159 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.